HDR brachytherapy in vivo source position verification using a 2D diode array: A Monte Carlo study by Poder, Joel et al.
University of Wollongong 
Research Online 
Faculty of Engineering and Information 
Sciences - Papers: Part B 
Faculty of Engineering and Information 
Sciences 
2018 
HDR brachytherapy in vivo source position verification using a 2D diode 
array: A Monte Carlo study 
Joel Poder 
University of Wollongong, jp132@uowmail.edu.au 
Dean L. Cutajar 
University of Wollongong, deanc@uow.edu.au 
Susanna Guatelli 
University of Wollongong, susanna@uow.edu.au 
Marco Petasecca 
University of Wollongong, marcop@uow.edu.au 
Andrew Howie 
St George Hospital 
See next page for additional authors 
Follow this and additional works at: https://ro.uow.edu.au/eispapers1 
 Part of the Engineering Commons, and the Science and Technology Studies Commons 
Recommended Citation 
Poder, Joel; Cutajar, Dean L.; Guatelli, Susanna; Petasecca, Marco; Howie, Andrew; Bucci, Joseph A.; and 
Rosenfeld, Anatoly B., "HDR brachytherapy in vivo source position verification using a 2D diode array: A 
Monte Carlo study" (2018). Faculty of Engineering and Information Sciences - Papers: Part B. 1857. 
https://ro.uow.edu.au/eispapers1/1857 
Research Online is the open access institutional repository for the University of Wollongong. For further information 
contact the UOW Library: research-pubs@uow.edu.au 
HDR brachytherapy in vivo source position verification using a 2D diode array: A 
Monte Carlo study 
Abstract 
Purpose 
This study aims to assess the accuracy of source position verification during high‐dose rate (HDR) 
prostate brachytherapy using a novel, in‐house developed two‐dimensional (2D) diode array (the Magic 
Plate), embedded exactly below the patient within a carbon fiber couch. The effect of tissue 
inhomogeneities on source localization accuracy is examined. 
Method 
Monte Carlo (MC) simulations of 12 source positions from a HDR prostate brachytherapy treatment were 
performed using the Geant4 toolkit. An Ir‐192 Flexisource (Isodose Control, Veenendaal, the Netherlands) 
was simulated inside a voxelized patient geometry, and the dose deposited in each detector of the Magic 
Plate evaluated. The dose deposited in each detector was then used to localize the source position using 
a proprietary reconstruction algorithm. 
Results 
The accuracy of source position verification using the Magic Plate embedded in the patient couch was 
found to be affected by the tissue inhomogeneities within the patient, with an average difference of 2.1 ± 
0.8 mm (k = 1) between the Magic Plate predicted and known source positions. Recalculation of the 
simulations with all voxels assigned a density of water improved this verification accuracy to within 1 
mm. 
Conclusion 
Source position verification using the Magic Plate during a HDR prostate brachytherapy treatment was 
examined using MC simulations. In a homogenous geometry (water), the Magic Plate was able to localize 
the source to within 1 mm, however, the verification accuracy was negatively affected by inhomogeneities; 
this can be corrected for by using density information obtained from CT, making the proposed tool 
attractive for use as a real‐time in vivo quality assurance (QA) device in HDR brachytherapy for prostate 
cancer. 
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Purpose: This study aims to assess the accuracy of source position verification dur-
ing high-dose rate (HDR) prostate brachytherapy using a novel, in-house developed
two-dimensional (2D) diode array (the Magic Plate), embedded exactly below the
patient within a carbon fiber couch. The effect of tissue inhomogeneities on source
localization accuracy is examined.
Method: Monte Carlo (MC) simulations of 12 source positions from a HDR prostate
brachytherapy treatment were performed using the Geant4 toolkit. An Ir-192 Flex-
isource (Isodose Control, Veenendaal, the Netherlands) was simulated inside a vox-
elized patient geometry, and the dose deposited in each detector of the Magic
Plate evaluated. The dose deposited in each detector was then used to localize the
source position using a proprietary reconstruction algorithm.
Results: The accuracy of source position verification using the Magic Plate embed-
ded in the patient couch was found to be affected by the tissue inhomogeneities
within the patient, with an average difference of 2.1  0.8 mm (k = 1) between the
Magic Plate predicted and known source positions. Recalculation of the simulations
with all voxels assigned a density of water improved this verification accuracy to
within 1 mm.
Conclusion: Source position verification using the Magic Plate during a HDR pros-
tate brachytherapy treatment was examined using MC simulations. In a homogenous
geometry (water), the Magic Plate was able to localize the source to within 1 mm,
however, the verification accuracy was negatively affected by inhomogeneities; this
can be corrected for by using density information obtained from CT, making the
proposed tool attractive for use as a real-time in vivo quality assurance (QA) device
in HDR brachytherapy for prostate cancer.
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1 | INTRODUCTION
When used in combination with external beam radiotherapy (EBRT)
in the form of a boost, high-dose rate (HDR) brachytherapy has been
shown to be a safe and effective treatment modality for intermedi-
ate- and high-risk prostate cancer.1,2 Despite recent technological
developments in the field of brachytherapy, such as image-guided
brachytherapy,3,4 treatment planning,5 electromagnetic tracking,6 and
applicator development,7–9 poor execution of HDR prostate
brachytherapy can still have a significant effect on patient outcomes.
Furthermore, the incidences of errors that may occur in the practice
of HDR prostate brachytherapy is relatively unknown, and limited
options exist for independent routine monitoring of treatment deliv-
ery. There are a number of published documents by the International
Commission on Radiological Protection (ICRP)10,11 as well as the
International Atomic Energy Association (IAEA)12 describing errors
that have occurred in HDR brachytherapy. Many of these errors are
related to human miscalculations, and less often, due to machine or
computational malfunction. The likelihood of remote afterloader mal-
function is generally considered extremely low; however, small devi-
ations from the plan in source dwell position and time can result in
significant errors in the dose delivered to the patient.13
The American Association of Physicists in Medicine (AAPM)
Radiation Therapy Task Group (TG) No. 5914 recommends that insti-
tutions employ a quality assurance (QA) program that exploits redun-
dancy and review the entire treatment planning and delivery process
to isolate any actions susceptible to errors. The report suggests that
incidence of these errors may be reduced by the introduction of pre-
treatment QA in the time between treatment planning and delivery.
Further to this, another AAPM Report from TG 5615 recommends
that the source position, source dwell time, and transit time be
quantified by the medical physicist on a regular basis. A combination
of these regular and pretreatment QA checks, along with a well-
documented treatment planning and delivery protocol will go a long
way to ensuring safe and successful delivery of HDR brachytherapy
treatment plans. However, this type of QA program will not safe-
guard the HDR brachytherapy delivery from all types of errors. An
ideal system for HDR brachytherapy treatment verification should be
able to provide real-time identification of the dwell positions, mea-
sure the dwell and transit times, and compare these parameters with
the prescribed treatment plan both before and during treatment.16
Real-time source identification of dwell positions during HDR
prostate brachytherapy treatments based on electronic portal imag-
ing devices (EPIDs) have been performed previously.17–19 In one
study, the authors retrospectively compared the planned vs mea-
sured source positions using an EPID embedded into the couch for
eight treatment fractions, and the mean linear distance between the
planned and measured dwell positions was found to be 1.8 mm
(range 0.7–3.9 mm).17 However, these EPID-based devices suffer
from low frame rates and slow readout electronics, resulting in loss
of data for short dwell times.18
This study aims to investigate the feasibility of using a two-
dimensional (2D) diode array, the “Magic Plate” (MP), developed at
the Centre for Medical Radiation Physics (CMRP), University of Wol-
longong (UoW), Australia, for in vivo source position verification of a
HDR prostate brachytherapy treatment. Previous studies performed
with the MP in homogeneous phantom media and have reported
source localization accuracy of less than 1 mm16,20,21 and temporal
resolution of 1 ms,20 making it an ideal device for real-time source
position verification. It is hypothesized that the introduction of
heterogeneous media associated with the patient geometry may
compromise the accuracy of source localization using this device.
To assess the feasibility of source localization using the MP in
the presence of patient-related heterogeneities, MC simulations
were performed using the Geant4 toolkit (v4.10.01).22,23 During the
HDR prostate brachytherapy treatment simulations, the Flexisource
Ir-192 source (Isodose Control, Veenendaal, the Netherlands) was
simulated inside a voxelized patient geometry, and the dose depos-
ited within the sensitive volume of each detector in the couch
embedded 11 9 11 diode array was evaluated. The simulated detec-
tor dose was then used to determine the distance of all detectors in
the array to each of the simulated source positions. Finally, the
source position was determined using an iterative procedure where
the source position is first estimated, and then repeatedly refined
based upon the agreement of the predicted geometric distance from
the source to the detectors against those determined by the detec-
tors in the array.
2 | MATERIALS AND METHODS
2.A | Ir-192 Flexisource
The geometric design of the Flexisource model was obtained from
the study performed by Granero et al.24 and is shown in Fig. 1. A
detailed description of the Flexisource model used in the simulations
is included in Appendix I.
2.B | Magic Plate diode array
The MP is a 2D silicon diode array developed at the CMRP, UoW,
Australia, originally as a tool for intensity modulated radiation ther-
apy (IMRT) QA.25,26 The MP has since been validated as a tool for
Ir-192 source position verification with focus on pretreatment qual-
ity assurance.16,21
The MP consists of an 11 9 11 array of epitaxial diodes
mounted on a 0.6 mm Kapton substrate using the “drop-in” tech-
nique. The structure of the MP is modeled in the Geant4 MC simula-
tions in this study using the description by Wong, et al.25 and is
shown in Figs. 2(a) and 2(b).
2.C | TG-43 simulations
Before using the Flexisource model in MC studies, the physics mod-
eling within the prospective MC simulations was validated against
benchmark data via TG-43 simulations. The AAPM TG43-U1
report27 recommends that MC simulations used to obtain TG-43
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parameters be performed with the source placed in the center of a
spherical 400 mm radius water phantom, so as to simulate an
unbounded phantom.28 The phantom geometry used in this simula-
tion was a 400 mm radius spherical phantom comprised of liquid
water with physical density 0.998 g/cm3. The density of 0.998 g/
cm3 was chosen so as to simulate the density of liquid water at
22°C as is recommended in TG43-U1.27
The spectrum of gamma energies emitted from the Ir-192 source
was obtained from the NuDat database.29 The b spectrum was not
considered in the study since its contribution to the dose delivered
beyond the stainless steel shell is negligible.24,30 A total of 109
primary photons were generated for each simulation run, and a total
of 10 simulation runs were performed. Results from each run were
averaged and the standard deviation (k = 1) calculated.
The interaction processes for photons (the photoelectric effect,
Compton scattering and Rayleigh scattering) are modeled using the
Geant4 Livermore Low Energy Package. The interactions cross-sec-
tions tabulation was taken from the EPDL97 database.31 In order to
improve the efficiency of the simulations, the linear track-length kerma
estimator32 was utilized with a photon cutoff energy of 250 eV.
Interactions for electrons (multiple scattering, ionization, and
bremsstrahlung) are also modeled using the Geant4 Livermore Low
F I G . 1 . Schematic of Flexisource Ir-192
source24 modeled in this study. All
dimensions are in millimeters.
(a)
(b)
F I G . 2 . (a) Schematic of the Magic
Plate diode spacing, the origin of the
coordinate system is defined as the bottom
left corner diode of the Magic Plate, (b)
Close up of the diode design (distances in
mm).
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Energy Package. Secondary particles with range less than 1 lm are
assumed to deposit the dose locally in the interaction voxel.30
To obtain the dose rate in polar coordinates and calculate the
TG-43 parameters, the dose was scored in spherical sections with
thickness of 0.5 mm (from 0 to 200 mm) and angular resolution of
1° (from 0° to 180°) concentric to the longitudinal axis of the source.
The thickness and resolution of the voxels were chosen so as to
ensure the effects of volume averaging was less than 0.1% for dis-
tances greater than 5 mm from the source.33 To calculate the
absorbed dose in each of the spherical sections, the total energy
deposited in each section was obtained and divided by the total
mass of the section.
The Ir-192 source is located at the origin of the calculation vol-
ume with its longitudinal axis placed along the y axis of the coordi-
nate system, as shown in Fig. 1. To calculate the radial dose
function, the absorbed dose along the z axis was normalized to the
absorbed dose at 10 mm from the center of the source, before
being divided by the normalized (at z = 10 mm) line source geometry
function, as per eq. (6) of the AAPM TG43-U1 report.27
To calculate the 2D anisotropy function, for a given radial dis-
tance from the center of the source (r) the absorbed dose was plot-
ted as a function of the angle from the longitudinal axis (h),
normalized to h = 90°, and then divided by the normalized (again at
h = 90°) line source geometry function, as shown in Equation 8 of
the AAPM TG43-U1 report.27
2.D | Source position verification simulations
Once the Flexisource model had been validated through TG-43 sim-
ulations, the same source was simulated inside a voxelized patient
model, and the dose deposited in each of the diodes in the carbon
couch embedded MP was tallied. The MP was modeled in the source
position verification simulations as described in Section 2.B, embed-
ded inside a 120-mm thick carbon couch, offset 5 mm from its ante-
rior surface.
The patient model was created by converting a DICOM CT study
set from a prostate HDR brachytherapy treatment into a voxelized
model that can be used in Geant4, as shown in Fig. 3. This was
achieved by first converting the Hounsfield unit (HU) numbers to a
mass density value using a CT–density curve, and then converting
from mass density to a material using a look up table.34–36 Once
imported into the simulation, a geometrical phantom is created,
within which is an array of voxels containing the materials (and their
compositions) determined from the HU numbers.36 The compositions
and the densities of materials used in the simulations were obtained
from the AAPM TG 186 Report.37 The voxel size was set to
3 9 3 9 3 mm3 in this study, to model an accurate geometrical defi-
nition of patient-related inhomogeneities and prevent prohibitively
long simulation times.
A selection of 12 source positions from a HDR prostate
brachytherapy treatment plan created in the Oncentra Brachyther-
apy treatment planning system (Elekta Brachytherapy, Veenendaal,
the Netherlands) were used in the simulations. The source position
coordinates were selected as three consecutive source positions
from four catheters. The catheters were selected such that they
spanned the extent of the prostate (L–R and A–P), to determine if
consecutive source positions along a catheter could be localized by
the MP at the maximum and minimum distances expected in a clini-
cal HDR prostate brachytherapy treatment. The step size of the
source used in the treatment planning system was 3 mm.
The same geometrical source model as described in Section 2.A
was used in the simulations, along with the same gamma spectrum
and interaction processes described in Section 2.C. To prevent over-
lapping volumes, which causes tracking errors in simulations, a paral-
lel geometry was used to place the source within the patient
geometrical phantom at the planned dwell positions.38 To calculate
the absorbed dose in each of the sensitive silicon volumes, the total
energy deposited in each volume was obtained and divided by the
total mass of the volume. Each source position was simulated with
109 primary photons for each simulation run. A total of 20 simula-
tion runs were performed for each source position; results from each
run were averaged and the standard deviation (k = 1) was less than
1%.
Each of the source localization simulations was then repeated
with each voxel in the patient geometry overridden to the density of
water, to compare the source localization accuracy of the MP with
and without the presence of patient-related inhomogeneities.
To determine the distance of each of the 12 source positions to
all detectors in the array (ai), a separate group of simulations were
first performed to determine the dose deposited in a single detector
placed at 10 mm from the source (D10), along the z axis (as shown
in Fig. 1) in a water phantom. A total of 10 simulations of 109
F I G . 3 . Partial axial view of voxelized patient geometry in Geant4
source position simulations. The carbon couch is shown below the
patient geometry outlined in green, the Kapton substrate in blue,
and the diode array in pink.
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primary photons were performed for this configuration, and the dose
deposited in the single detector averaged across the 10 simulations.
This average dose was then used to normalize the dose from each
detector in the patient geometry simulations (Di), before converting





The radial distance from each detector to each source position
can then be determined by converting the relative diode dose to dis-
tance via a fit of the TG-43 parameters calculated in Section 2.C.
This approach assumes that the diodes are present within a homoge-
neous water phantom, when in fact the diode dose was calculated
within the heterogeneous patient voxelized phantom. The source
positions were determined using an iterative procedure (Appen-
dix 2).39,40 Once an initial estimation of the source position is found,
a correction factor is then applied to the response of each of the
MP detectors to take into account the angular dependence of the
detectors. The source position is then re-estimated using the above
method but uses the initial estimated source position of the previous
calculation. Finally, the calculated source position is compared to
known source positions obtained from the Oncentra Brachytherapy
treatment planning system.
3. | RESULTS
3.A | TG-43 simulations
The radial dose function and anisotropy function (at a radial distance
of 10 mm) calculated in this study, using an active length of 3.5 mm
for the calculation of GL(r,h), are compared to Granero et al.
24 and
Taylor & Rogers41 in Figs. 4 and 5, respectively.
The calculated radial dose function from this study was shown
to agree (discrepancies < 1%) with both the Granero24 and Taylor &
Rogers41 benchmark datasets within the calculated uncertainty
(1.2%) in the radial distance range of 1–200 mm. The 2D anisotropy
was also found to agree with the two benchmark datasets to within
1% across the investigated range, verifying the source model and
simulation physics were adequate to be used in the study. Larger
discrepancies can be observed at polar angles between 0–15° and
165–180° due to the minor variations in source capsule modeling
between the studies. In this study, the non-cable end weld of the
stainless steel shell is modeled as a cylinder of length 0.65 mm and
diameter 0.85 mm, whereas in the studies by Granero et al.24 and
Taylor & Rogers41 the end weld is modeled as a 0.108 mm thick
conical section with a half angle of 23° and the radius of the face
being 0.17 mm. This conical section was then attached to a
0.49 mm long solid cylindrical section to complete the end weld.
This minor difference in the end weld modeling was not observed to
have a significant effect on the calculated anisotropy. There is also a
substantial decrease in magnitude of the dose scored in the voxels
close to the ends of the source encapsulation due to the significant
attenuation through the end welds, this leads to an increased
statistical uncertainty and may also contribute to the larger discrep-
ancies in calculated anisotropy between the studies.
3.B | Source position verification simulations
The average difference between MP predicted and actual source
positions was found to be 2.1  0.8 mm (k = 1) when all detectors
in the array were used in the localization algorithm. Table 1 summa-
rizes the localization results in three dimensions, along with the cal-
culated three-dimensional difference vector, for different number of
detectors used in the source localization algorithm. When not all
detectors in the array were used in the source position verification
algorithm, the detectors with the highest deposited dose were cho-
sen. As can be seen from Table 1, the MP could localize the source
F I G . 4 . Comparison of calculated radial dose function with studies
by Granero24 and Taylor & Rogers.41
F I G . 5 . Comparison of calculated 2D anisotropy function at a
radial distance of 10 mm with studies by Granero24 and Taylor &
Rogers.41
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to within 1 mm in the X and Y directions (left/right and superior/in-
ferior directions, respectively). However, it consistently overesti-
mated the distance in the Z direction (anterior/posterior direction),
with an average error of 1.9 mm.
The source position verification simulations were then repeated
using the exact same methods, but with each voxel in the patient
geometry assigned a density of water [Figs. 6(a)–6(d)]. The heteroge-
neous and water only results were compared by means of a Stu-
dent’s t test (P < 0.05) in each of the X, Y, and Z directions. Only
the Z direction differences were found to be statistically significant
(P < 0.001).
The heterogeneous results were used for a one-way ANOVA42
analysis (P < 0.05) to determine if there was a statistically significant
difference in the localization accuracy depending on the number of
detectors used. The only significant difference was found for the
three-dimensional vector (P < 0.001). Subsequent Student’s t tests
were performed to compare the datasets for the three-dimensional
vector. From this, it was found that only the dataset with nine
detectors had statistically significant differences to the other groups.
TA B L E 1 Difference between MP predicted and actual source




used 9 25 49 81 121
X 0.5  1.0 0.2  0.4 0.0  0.2 0.0  0.2 0.2  0.2
Y 0.5  1.1 0.0  0.5 0.0  0.3 0.2  0.3 0.5  0.5
Z 1.8  0.5 1.8  0.5 1.9  0.5 2.0  0.5 2.0  0.5
3D 2.4  1.0 1.9  0.5 1.9  0.5 2.0  0.5 2.1  0.6
(a) (b)
(c) (d)
F I G . 6 . (a) Difference between MP predicted and actual source position for heterogeneous and water only simulations in X direction, (b)
difference in Y direction, (c) difference in Z direction, and (d) 3D difference vector. Coordinate system orientation is shown in Figs. 1 and 2.
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4 | DISCUSSION
The uncertainties quoted in this study have been evaluated using
the combination of both type A and type B uncertainties combined
in quadrature, as recommended in AAPM TG43-U127 and AAPM
TG138.43 A summary of the uncertainty budget for both the TG-43
simulations and the source tracking simulations is presented in
Table 2.
In a water only geometry, the Magic Plate was able to localize
the source to within 1 mm. The source localization accuracy, how-
ever, was found to decrease with the introduction of inhomo-
geneities. This decrease in accuracy of source position localization
due to the presence of inhomogeneities was found to be primarily in
the direction perpendicular to the diode array (z direction). This is
due to the source localization algorithm39,40 z direction estimate
being more sensitive to the changing ratio of primary to secondary
photons due to the presence inhomogeneities and increased source
to detector distance.
The distance estimate in the z direction is depends directly on
the absolute dose deposited in the detector array, whereas source
localization in the x and y directions depends only on the relative
difference between the distance estimate for each detector and
therefore is less sensitive to inhomogeneities. Small inhomogeneities,
however, can affect the x and y estimate if a smaller number of
detectors are used in the localization algorithm.39,40
This indicates that to track the Ir-192 source with the desired
accuracy during HDR prostate brachytherapy treatments a correction
may be required, based on density information obtained from the
patient CT scan performed prior to treatment. This information could
be used, along with a model-based dose calculation algorithm37 built
into the localization algorithm to more accurately predict the source
to detector distances.
Moreover, it was found that source localization accuracy can be
improved with an increased number of detectors used in the localiza-
tion algorithm. By increasing the number of detectors used in the local-
ization algorithm, a redundancy is built in to reduce the uncertainty
introduced due to small heterogeneous media in the patient geome-
try.47 The increased number of detectors is also beneficial due to the
relatively isotropic dose profile at large source to detector distances.40
Previous studies have shown that source position verification
using EPIDs is achievable. However, these studies have also shown
that source position verification using EPIDs is restricted by the lim-
ited frame rate and readout electronics of the devices and can result
in a significant number of dwell positions not being captured by the
EPID when performing source position verification.18 Source position
verification using EPIDs also requires large and expensive systems
that have limited availability. This study has shown that similar
source position verification accuracy to EPIDs17–19 may be achieved
with the MP system. Furthermore, the MP system has been shown
to have a superior timing resolution of less than 1 ms.20 As such,
the MP delivers a dedicated, inexpensive HDR brachytherapy in vivo
source position verification system with superior timing resolution
that can easily be mass produced and is practical for routine clinical
use.
The results of this study, along with previously published experi-
mental results,16,40 indicate that the MP will have sufficient sensitiv-
ity to detect errors in the order of 1–2 mm during the delivery of
HDR prostate brachytherapy treatments when embedded in a car-
bon fiber couch beneath the patient. Such errors may be due to
incorrect catheter connection or incorrect source strength. However,
discrepancies less than 1–2 mm in catheter reconstruction, and small
movements of catheters in the time between simulation and treat-
ment may not be detectable unless patient-related heterogeneities
can be taken into account during source position verification. Fur-
thermore, one of the most significant challenges for clinical imple-
mentation of source position verification using the MP system is the
registration of MP and patient coordinate systems. Previous studies
have overcome this challenge by using stereoscopic imaging,17,48
and electromagnetic tracking technology.49,50 Overcoming this chal-
lenge will be a focus in future publications.
With the move toward real-time prostate brachytherapy treat-
ment planning based on transrectal ultrasound imaging, future stud-
ies will also aim to examine the effect of the ultrasound probe on
source localization accuracy and attempt to optimize the MP posi-
tion to minimize the effects of heterogeneities.
5 | CONCLUSION
Source localization using the Magic Plate during a HDR prostate
brachytherapy treatment was examined using MC simulations. In a
homogenous geometry, the Magic Plate was able to localize the
TA B L E 2 Uncertainty analysis for MC simulations used in this study.
Type A Type B
Statistical variation in absorbed dose determination from repeated MC simulation runs 1%
Variations of the source geometry from one source to another in manufacturing process24 0.5%
Uncertainty in cross-section library data for Ir-19244 0.5%
Effect of volume averaging on absorbed dose calculation in sensitive volumes45 0.1%
Uncertainty in composition of tissues used during source tracking simulations46a 2%
Total TG-43 simulation uncertainty 1.2%
Total source tracking simulation uncertainty 2.3%
aApplies to source tracking simulations only.
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source to within 1 mm. The effect of tissue inhomogeneities in the
patient geometry on source localization accuracy was also examined
and was found to increase the difference between Magic Plate pre-
dicted and known source positions from the brachytherapy treat-
ment planning system to 2.1  0.81 mm (k = 1). However, this
accuracy can be improved using density information obtained from
CT with the MP accurately registered to the patient geometry, mak-
ing the proposed tool attractive for use as a real-time in vivo QA
device in HDR brachytherapy for prostate cancer.
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APPENDIX 1
DESCRIPTION OF IR-192 FLEXISOURCE
MODEL
The Ir-192 core is modeled as a pure Iridium cylinder of length 3.5 mm
and diameter 0.6 mm; it has a physical density of 22.42 g/cm3.
The active Ir-192 core is surrounded by a stainless steel shell of
length 4.6 mm, 0.85 mm outer diameter, and inner diameter of
0.67 mm. This results in a shell thickness of 0.09 mm. The composi-
tion by weight of the stainless steel shell is modeled as follows: Fe
67.92%, Cr 19%, Ni 10%, Mn 2%, Si 1%, and C 0.08%, and the phys-
ical density is 7.999 g/cm3.
The non-cable end weld of the stainless steel shell is modeled as
a cylinder of length 0.65 mm and diameter 0.85 mm. The cable end
weld of the stainless steel shell is modeled as a partial cone of maxi-
mum diameter 0.85 mm, minimum diameter of 0.5 mm, and length
0.4 mm.
Finally, the stainless steel cable is modeled as a cylinder of
5 mm length and 0.5 mm diameter, as recommended by Granero
et al.24 The space between the outer stainless steel shell and the





Based on the derived distances (ri) of each diode (i) in the array to
the source, as described in Section 2.D, the estimated source posi-
tion, Ses(a,b,c) can be calculated. The geometrical distance, di,





2 þ ðb yiÞ




To determine the true source position, the geometrical distance,
di, is fitted to the derived distance, ri, by adjusting the estimated
source position. Employing a nonlinear least squares fit method to
determine the estimated source position. In least squares fitting, the
estimate of error assessment can be expressed as the sum of








and assumes that the derived distance, ri, is correct. As there is an
uncertainty associated with deriving ri, if the estimated source posi-
tion were equal to the true source position, then calculating the
square of the sums of the percentage difference of the value di and
ri would result in a minimum value.
To determine a source position that gives the minimal value to
the estimate Χ2 a multivariable Newtown’s method approach is
adopted. The Newton’s method is used in this case to determine the
roots of a function by finding successively better approximations. In
this analysis, it is necessary to determine the minimum values of Χ2
for all three dimensions of the estimated source position, and can be
expressed as










The Newton’s method for the three source coordinates can be
expressed for the k-th iteration as
ak ¼ ak1  dak1
bk ¼ bk1  dbk1
ck ¼ ck1  dck1
(A4)
where da, db, and dc are the changes made to the source position to
produce the improved approximation. These changes can be deter-




















































































This process is repeated until all d’s are sufficiently small, or until
further estimations of the source coordinates fail to reduce Χ2. This
approach can converge rapidly to a minimum when close, as all three
source coordinates are modified in a single iteration.
The initial guess is determined by the coordinates of the detector
with the highest response, Dmax(xmax,ymax,z = 0), as the source is
assumed to be closest to this position. The sum of the squares is cal-
culated using the first estimation of the source position,
S0es ¼ ða
0
; b0; c0Þ ¼ Sesðxmax; ymax; rmaxÞ (A6)
The source position is then re-estimated using the above
method, but uses the initial estimated source position of the previ-
ous calculation.
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